PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will host a virtual “Spotlight Event” on Wednesday, November 10, 2021 at 11:00 a.m. Eastern Time. The event will focus on UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer (LG-NMIBC), and the Company’s earlier-stage clinical programs including UGN-301 and UGN-302.
In addition to presentations from UroGen’s Chairman Arie Belldegrun, M.D. and members of the Company’s senior management team, the program will include a Key Opinion Leader panel discussion on the treatment of NMIBC.
Please register for the webinar on the Company's website at www.urogen.com under the Events & Presentations section of the Investor Relations site (https://investors.urogen.com/events-and-presentations).
Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
Third Quarter 2021 Financial Results
Additionally, the Company announced that it will report third quarter 2021 financial results on Monday, November 15, 2021, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.
The webcast will be available on the Investors section of the Company’s website at http://investors.urogen.com. Following the live audio webcast, a replay will be available on the Company's website for 30 days.
Live (U.S. / Canada): (855) 765-5685
Live (International): (615) 247-5916
Confirmation number: 1908609
About UroGen Pharma Ltd.
UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.